Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 2029-2036

  Chen, Chih Cheng ^a,b   Gau, Jyh Pyng ^c,d   Chou, Hui Ju ^a   You, Jie Yu ^d,e   Huang, Cih En ^a   Chen, Yi Yang ^a   Lung, Jrhau ^a   Chou, Yi Sheng ^d,e   Leu, Yu Wei ^f   Lu, Chang Hsien ^a,b   Lee, Kuan Der ^a,b   Tsai, Ying Huang ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e LOTUNG POH AI HOSPITAL   (Taiwan)

^f NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

CALR mutation; Essential thrombocythemia; JAK2 mutation; MPL mutation; Myeloproliferative neoplasm

Indexed keywords

CALRETICULIN; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID SEQUENCE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; GENE DELETION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; MULTICENTER STUDY; MUTATION; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SPLENOMEGALY; TAIWAN; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOPHILIA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CALRETICULIN; FEMALE; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PLATELET COUNT; PROPORTIONAL HAZARDS MODELS; RECEPTORS, THROMBOPOIETIN; SEQUENCE ALIGNMENT; SEQUENCE DELETION; SEQUENCE HOMOLOGY, AMINO ACID; SPLENOMEGALY; TAIWAN; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPHILIA; YOUNG ADULT;

EID: 84922211200     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2151-8     Document Type: Article

References (25)

1. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22
2. Tefferi A (2008) The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22:3–13
3. Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459–468
4. Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270
5. Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573–582
6. Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405
7. Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390
8. Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544–1551
9. Rotunno G, Mannarelli C, Guglielmelli P et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123:1552–1555
10. Swerdlow SHCE, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon
11. Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437–438
12. Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770
13. Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846
14. Bench AJ, White HE, Foroni L et al (2013) Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 160:25–34
15. Kroger N, Badbaran A, Holler E et al (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109:1316–1321
16. Beer PA, Campbell PJ, Scott LM et al (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112:141–149
17. Chaligne R, Tonetti C, Besancenot R et al (2008) New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 22:1557–1566
18. Pecquet C, Staerk J, Chaligne R et al (2010) Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 115:1037–1048
19. Rumi E, Pietra D, Guglielmelli P et al (2013) Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 121:4388–4395
20. Martinez-Aviles L, Alvarez-Larran A, Besses C et al (2012) Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia. Ann Hematol 91:1555–1562
21. Passamonti F, Thiele J, Girodon F et al (2012) A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 120:1197–1201
22. Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120:5128–5133, quiz 5252
23. Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857–5859
24. Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. doi:10.1038/leu.2014.3
25. Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 vs Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol doi:10.1002/ajh.23743